Back Blockbuster Press News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MindMed Will Use the Proceeds of the Offering for Investment in its Digital Medicine Division, for Further Investments in its Project Lucy and Project Layla, for its LSD Micro-Dosing ADHD Trials and for General Working Capital Purposes MindMed (OTCQB:MMEDF) announced that further to its previously announced offering on December 14 and December 15, 2020, it has filed a preliminary short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec. Pursuant to the underwriting agreement among the company, the underwriters Canaccord Genui...

Based on Positive Pre-IND Meeting With FDA, MindMed is Now Prepared to Open an Investigational New Drug (IND) in August 2021 With a Phase 2B Clinical Trial for LSD Assisted Therapy in Anxiety MindMed (OTCQB:MMEDF) announced the successful completion of a pre-IND (Investigational New Drug) meeting with the U.S. FDA regarding the development of LSD assisted therapy for an anxiety disorder. MindMed also provided a clinical development update on 18-MC announcing the firm continues to dose escalation of 18-MC in Phase I SAD/MAD and has confirmed a meeting with the FDA.